Boulder Ventures

SEC exempt reporting adviser (venture capital exemption).

Website: https://www.boulderventures.com
HQ: CO

Boulder Ventures is a venture capital firm focused on IT and biotech companies in Colorado and the Mid-Atlantic. Its team includes general partners Kyle Lefkoff, Peter Roshko, Kishen Mangat, and Jonathan Perl, along with chief financial officer Matthew Paul. The firm has invested in Ambrosia Biosciences Inc.

01 · Says / Does

Tag	Says	Does	Historically (to 2020)
Stages	Not stated	Not enough dated deals	Series A, Growth, Series B
Sectors	Biotech	Not enough dated deals	Enterprise SaaS, Biotech, Hardware, Data analytics, Healthtech, Medical devices
Regions	CO	Not enough dated deals	CO, VA

Says: what the firm's funds state. Does: from 1 dated deal in the last 24 months.

Historical focus (through 2020), derived from historical deal data.

Year	Deals	Top sectors
1999	2	Hardware, Manufacturing
2000	6	Construction and proptech, Data analytics, Govtech
2001	9	Enterprise SaaS, Hardware, Healthtech
2002	3	Ecommerce, Enterprise SaaS, Hardware
2003	5	Hardware, Enterprise SaaS
2004	1	None
2005	4	Hardware, Ecommerce, Enterprise SaaS
2006	10	Enterprise SaaS, Biotech, Healthtech
2007	7	Biotech, Data analytics, Healthtech
2008	7	Enterprise SaaS, Biotech, Data analytics
2009	6	Enterprise SaaS, Ecommerce, Medical devices
2010	4	Data analytics, Enterprise SaaS, Life sciences and research tools
2011	4	Data analytics, Media, Enterprise SaaS
2012	4	Biotech, Enterprise SaaS, Hardware
2014	5	Enterprise SaaS, Media, Biotech
2015	5	Biotech, Healthtech, Medical devices
2016	3	Construction and proptech, Data analytics, Energy
2017	4	Enterprise SaaS, Biotech, Construction and proptech
2018	3	Enterprise SaaS, Biotech, Life sciences and research tools
2019	4	Biotech, Life sciences and research tools, Advanced materials

Stage mix over time

Pre-seed
Seed
Series A
Series B
Growth

Share of rounds by stage, per year. Striped years have fewer than 3 rounds.Historical focus (through 2020), derived from historical deal data.From public announcements.

Rounds by stage and year
Year	Seed	Series A	Series B	Growth
2010	0	0	1	1
2011	0	1	0	2
2012	0	0	1	2
2013	0	0	0	0
2014	0	3	2	0
2015	0	1	2	2
2016	1	2	0	0
2017	0	3	0	1
2018	0	1	0	2
2019	0	1	2	1
2020	0	0	0	0
2021	0	0	1	0
2022	0	0	0	0
2023	0	0	0	0
2024	0	0	0	0
2025	1	0	0	0
2026	0	1	0	0

02 · Fund history

Fund	Year	Size	Status
Boulder Ventures IX, L.P. Boulder Ventures is a venture capital firm that invests in IT and biotech companies in Colorado and the Mid-Atlantic region. Inferred from the firm's website	approx. 2026	$60M (Form D)	Raising
Boulder Ventures VIII, L.P. Boulder Ventures is a venture capital firm that invests in IT and biotech companies in Colorado and the Mid-Atlantic region. Inferred from the firm's website	2022	$58.23M to $100M (Form D)	Late investment period

03 · People across funds

Jonathan Perl, General Partner
Boulder Ventures IX, L.P. (Named on Form D); Boulder Ventures VIII, L.P. (Named on Form D)
Kishen Mangat, General Partner
Boulder Ventures IX, L.P. (Named on Form D); Boulder Ventures VIII, L.P. (Named on Form D)
Kyle Lefkoff, General Partner
Boulder Ventures IX, L.P. (Named on Form D); Boulder Ventures VIII, L.P. (Named on Form D)
Peter Roshko, General Partner
Boulder Ventures IX, L.P. (Team); Boulder Ventures VIII, L.P. (Named on Form D)
Matthew Paul, Chief Financial Officer
Boulder Ventures IX, L.P. (Team); Boulder Ventures VIII, L.P. (Team)
Revelstoke the Berner, Floor Manager
Boulder Ventures IX, L.P. (Team); Boulder Ventures VIII, L.P. (Team)

04 · Recent deals

Apr 1, 2026Ambrosia Biosciences Inc.Series BFirmsource

05 · Latest from the firm

InvestmentAmbrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline — Boulder Ventures Ltd.Apr 1, 2026

06 · Sources

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026